126 related articles for article (PubMed ID: 38618837)
1. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
Zhou J; Lu H; Pan J
Int J Health Policy Manag; 2024 Mar; ():. PubMed ID: 38618837
[TBL] [Abstract][Full Text] [Related]
2. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
3. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
[TBL] [Abstract][Full Text] [Related]
4. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
Rossini EE; Galeone C; Lucchetti C; Jommi C
Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
[TBL] [Abstract][Full Text] [Related]
5. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
Ling K; Qin H; Feng Y; Che H; Ding J; Li W
Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
[TBL] [Abstract][Full Text] [Related]
6. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
7. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
8. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
9. The reimbursement decision speed for oncology new drugs in China and its determinant factors.
Zhu X; Chen Y
Front Public Health; 2023; 11():1207739. PubMed ID: 38026304
[TBL] [Abstract][Full Text] [Related]
10. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.
Luo X; Du X; Huang L; Guo Q; Lv X; Wang C; Liu H; Zhou Y; Xue X; Li Z; Liu J; Chow SC; Yang Y
EClinicalMedicine; 2023 Sep; 63():102177. PubMed ID: 37662522
[TBL] [Abstract][Full Text] [Related]
11. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study.
Pan J; Wei X; Lu H; Wu X; Li C; Hai X; Lan T; Dong Q; Yang Y; Jakovljevic M; Zhou J
Lancet Reg Health West Pac; 2024 Jun; 47():101088. PubMed ID: 38774422
[TBL] [Abstract][Full Text] [Related]
12. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli DT; Michaeli T
Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
[TBL] [Abstract][Full Text] [Related]
13. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Goldhaber-Fiebert JD; Cipriano LE
Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical trial designs for novel anticancer drugs in China: A cohort study of drugs approved between 2015 and 2021.
Luo X; Guo Q; Du X; Huang L; Chow SC; Yang Y
Drug Discov Today; 2023 Jun; 28(6):103578. PubMed ID: 37004982
[TBL] [Abstract][Full Text] [Related]
15. Bridging the new drug access gap between China and the United States and its related policies.
Zhu X; Chen Y
Front Pharmacol; 2023; 14():1296737. PubMed ID: 38259295
[No Abstract] [Full Text] [Related]
16. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
[TBL] [Abstract][Full Text] [Related]
17. Launch Delay of New Drugs in China and Effect on Patients' Health.
Zhu X; Liu B
Clin Ther; 2020 Sep; 42(9):1750-1761.e7. PubMed ID: 32798058
[TBL] [Abstract][Full Text] [Related]
18. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.
Bao Y; Liu Y; Ma R; Zhang P; Li X
J Glob Health; 2023 Nov; 13():04140. PubMed ID: 37934965
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
